Overall, these data indicate that the simultaneous inhibition of BRD4S and LOXL2 successfully reduces tumor growth by suppressing TNBC cell proliferation and inducing cell death, holding exciting potential for the development of future clinical applications. The gene discussed is LOXL2; the disease is neoplasm.